Your search for dabigatran returned 11 results

Compared with other DOACs, rivaroxaban linked to higher rates of GI bleeding overall and in an analysis restricted to patients with atrial fibrillation

Dabigatran Etexilate Capsules is a direct thrombin inhibitor indicated to reduce the risk of stroke and blood clots.

Study findings revealed an increased risk of surgical intervention in women exposed to rivaroxaban.

Investigators found an incremental increase in risks from oral anticoagulants as kidney function decreased, highlighting the need for more research to better understand bleeding risk and net benefit of treatment in the CKD population.

No substantial differences seen for other outcomes or for other direct oral anticoagulant comparisons

Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels

Although more research is needed, data suggest that the cardioprotective effect of direct oral anticoagulants may extend to patients with advanced CKD.

Findings may help with decision-making in this high-risk patient population.

Disparities seen among VA patients both for initiating any anticoagulant therapy and for initiating direct-acting oral anticoagulant use

Risks for ischemic stroke or systemic embolism, major bleeding events lower with DOACs overall as a class versus warfarin